NCT06747897Completed
An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin
Retrospective Consumer Experience on Former Use of DIPROBASE Advanced Eczema Cream® UI 1613882
Source: ClinicalTrials.gov · Last updated 17 Jan 2025
Brief summary (registry, in English)
This is an observational study which means only data are collected from participants about their experience and symptoms, who received their usual treatment without any intervention from the study sponsor. Atopic dermatitis, also known as eczema, is a long-lasting skin disease that causes redness, swelling, dryness, cracking, and intense itching. Xerosis is the scientific wording to describe dry skin. This condition is caused by a weakened skin barrier that does not hold moisture well. DIPROBASE® advanced eczema cream is already available for use in the UK. It moisturizes and protects the skin. This study is being done to understand how people use DIPROBASE® Advanced Eczema Cream and how consistently they adhere to its recommended use in their daily routines. In this study, participants will be asked to fill in an online questionnaire about their eczema symptoms and experience with DIPROBASE® Advanced Eczema Cream. No treatment advice will be given as a part of this study. The main purpose of this study is to gather feedback from people in the UK who have used DIPROBASE® Advanced Eczema Cream to treat their eczema or their dry skin condition. To do this, researchers will collect the following information from participants: * intensity of eczema symptoms * whether the cream provides a cooling or soothing effect * whether the cream helps to ease the symptoms like itchiness, pain, or dryness It is planned to identify and collect user data from November 2024 to January 2025. Participants will be recruited through a consumer database available with an external partner or via social media. In this study, only data are collected. No visits or tests are required as part of this study.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 300 (actual)
- First submitted
- 18 Dec 2024
- Start date
- 28 Nov 2024
- Primary completion date
- 12 Dec 2024
- Lead sponsor
- Bayer
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT06747897
What you commit to
- Study type: Observational
- Participants enrolled: 300
- From 28 Nov 2024 to the primary completion date, 12 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Due to the real-world nature of the study, there are no exclusion criteria.
Who the study is looking for
- Participants:
- Biological sex: M/F.
- Age: \> or equal to 18 years of age.
- Mothers, fathers, grandparents, and other caregivers aged 18 years of age and above, who will report data on themselves, their children from 2 to 12 years of age or their infants under 2 years of age.
- Able to read and understand the language of the online questionnaire.
- Have used the product within the previous three (3) months.
- Agree that the data collected can be used for research, marketing and regulatory purposes.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IQVIA Ltd. Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.